TY - JOUR
T1 - Post-acute sequelae of COVID-19
T2 - A metabolic perspective
AU - Scherer, Philipp E.
AU - Kirwan, John P.
AU - Rosen, Clifford J.
N1 - Funding Information:
Funder Grant reference number Author National Institute of General Medical Sciences U54GM11516-05 Clifford J Rosen The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.
Publisher Copyright:
© Scherer et al.
PY - 2022/3
Y1 - 2022/3
N2 - The SARS-CoV-2 pandemic continues to rage around the world. At the same time, despite strong public health measures and high vaccination rates in some countries, a post-COVID-19 syndrome has emerged which lacks a clear definition, prevalence, or etiology. However, fatigue, dyspnea, brain fog, and lack of smell and/or taste are often characteristic of patients with this syndrome. These are evident more than a month after infection, and are labeled as Post-Acute Sequelae of CoV-2 (PASC) or commonly referred to as long-COVID. Metabolic dysfunction (i.e., obesity, insulin resistance, and diabetes mellitus) is a predisposing risk factor for severe acute COVID-19, and there is emerging evidence that this factor plus a chronic inflammatory state may predispose to PASC. In this article, we explore the potential pathogenic metabolic mechanisms that could underly both severe acute COVID-19 and PASC, and then consider how these might be targeted for future therapeutic approaches.
AB - The SARS-CoV-2 pandemic continues to rage around the world. At the same time, despite strong public health measures and high vaccination rates in some countries, a post-COVID-19 syndrome has emerged which lacks a clear definition, prevalence, or etiology. However, fatigue, dyspnea, brain fog, and lack of smell and/or taste are often characteristic of patients with this syndrome. These are evident more than a month after infection, and are labeled as Post-Acute Sequelae of CoV-2 (PASC) or commonly referred to as long-COVID. Metabolic dysfunction (i.e., obesity, insulin resistance, and diabetes mellitus) is a predisposing risk factor for severe acute COVID-19, and there is emerging evidence that this factor plus a chronic inflammatory state may predispose to PASC. In this article, we explore the potential pathogenic metabolic mechanisms that could underly both severe acute COVID-19 and PASC, and then consider how these might be targeted for future therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=85126907539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126907539&partnerID=8YFLogxK
U2 - 10.7554/eLife.78200
DO - 10.7554/eLife.78200
M3 - Review article
C2 - 35318939
AN - SCOPUS:85126907539
VL - 11
JO - eLife
JF - eLife
SN - 2050-084X
M1 - e78200
ER -